Details of the Drug

General Information of Drug (ID: DMO946V)

• Drug Name: Ticlopidine
• Synonyms: Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1]
Myocardial infarction	BA41-BA43	Approved	[1]
Stroke	8B20	Approved	[2]

• Therapeutic Class: Fibrinolytic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 263.8
  Logarithm of the Partition Coefficient (xlogp); 3.6
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption: The absorption of drug is greater than 80% []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 80% of drug becomes completely available to its intended biological destination(s) [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7.9 hours (in subjects 20 - 43 years of age with 250 mg dose) [5]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.80795 micromolar/kg/day [6]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Liver injury	HLA-DQB1*06:04	HLA-DQB	OTVVI3UI	[7]
Liver injury	HLA-C*14:03	HLA-C	OTV38BUJ	[7]
Liver injury	HLA-B*44:03	HLA-B	OTNXFWY2	[7]
Liver injury	HLA-A*33:03	HLA-A	OTAH14LU	[7]

• Chemical Identifiers:
  Formula: C14H14ClNS
  IUPAC Name: 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
  Canonical SMILES: C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
  InChI: InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
  InChIKey: PHWBOXQYWZNQIN-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5472
  ChEBI ID: CHEBI:9588
  CAS Number: 55142-85-3
  DrugBank ID: DB00208
  TTD ID: D05LBU
  VARIDT ID: DR00842
  INTEDE ID: DR1592
  ACDINA ID: D00675
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-activating factor receptor (PTAFR)	TTQL5VC	PTAFR_HUMAN	Modulator	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Myeloperoxidase (MPO)	DEA3U9Y	PERM_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
HLA class I histocompatibility antigen, A alpha chain (HLA-A)	OTAH14LU	HLAA_HUMAN	Drug Response	[7]
HLA class I histocompatibility antigen, B alpha chain (HLA-B)	OTNXFWY2	HLAB_HUMAN	Drug Response	[7]
HLA class I histocompatibility antigen, C alpha chain (HLA-C)	OTV38BUJ	HLAC_HUMAN	Drug Response	[7]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Drug Response	[7]

Molecular Expression Atlas of This Drug

• The Studied Disease: Acute coronary syndrome
• ICD Disease Classification: BA41

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Platelet-activating factor receptor (PTAFR)	DTT	PTAFR	3.53E-02	0.33	2.12
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	6.05E-02	2.38E-01	2.17E+00
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.44E-02	-5.80E-01	-1.74E+00
Myeloperoxidase (MPO)	DME	MPO	3.56E-01	1.54E-01	1.04E+00

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ticlopidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Ticlopidine due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[11]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Ticlopidine caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[12]
Ranolazine	DM0C9IL	Minor	Decreased metabolism of Ticlopidine caused by Ranolazine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Clobazam - Lundbeck	DMW1OQ0	Moderate	Decreased metabolism of Ticlopidine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[14]
Cilostazol	DMZMSCT	Major	Decreased metabolism of Ticlopidine caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[15]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Ticlopidine caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[15]
Atomoxetine	DM5L6HI	Moderate	Decreased metabolism of Ticlopidine caused by Atomoxetine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[16]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Pentosan polysulfate.	Chronic pain [MG30]	[17]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Phenylbutazone.	Chronic pain [MG30]	[11]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Ketoprofen.	Chronic pain [MG30]	[11]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Levomilnacipran.	Chronic pain [MG30]	[18]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Anisindione.	Coagulation defect [3B10]	[19]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Ticlopidine and Regorafenib.	Colorectal cancer [2B91]	[15]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Intedanib.	Colorectal cancer [2B91]	[20]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Ticlopidine caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[15]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Ticlopidine and Ardeparin.	Coronary thrombosis [BA43]	[21]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Ticlopidine caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[22]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Ticlopidine and Danaparoid.	Deep vein thrombosis [BD71]	[21]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Ticlopidine and Rivaroxaban.	Deep vein thrombosis [BD71]	[23]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Sertraline.	Depression [6A70-6A7Z]	[18]
Fluoxetine	DM3PD2C	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Fluoxetine.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Vilazodone.	Depression [6A70-6A7Z]	[18]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Paroxetine.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Vortioxetine.	Depression [6A70-6A7Z]	[18]
Duloxetine	DM9BI7M	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Duloxetine.	Depression [6A70-6A7Z]	[18]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Milnacipran.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Escitalopram.	Depression [6A70-6A7Z]	[24]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Desvenlafaxine.	Depression [6A70-6A7Z]	[18]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Clomipramine.	Depression [6A70-6A7Z]	[18]
Venlafaxine	DMR6QH0	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Venlafaxine.	Depression [6A70-6A7Z]	[18]
Heme	DMGC287	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Heme.	Discovery agent [N.A.]	[25]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Ticlopidine and Apigenin.	Discovery agent [N.A.]	[26]
Citalopram derivative 1	DMITX1G	Major	Decreased metabolism of Ticlopidine caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[27]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Ticlopidine and PMID28870136-Compound-49.	Discovery agent [N.A.]	[28]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[18]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ticlopidine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Phenytoin	DMNOKBV	Moderate	Decreased metabolism of Ticlopidine caused by Phenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Ticlopidine caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Ticlopidine caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Ethotoin	DMXWOCP	Moderate	Decreased metabolism of Ticlopidine caused by Ethotoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Phenobarbital	DMXZOCG	Minor	Decreased metabolism of Ticlopidine caused by Phenobarbital mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Ticlopidine caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[15]
Timolol	DM3NXRU	Moderate	Decreased metabolism of Ticlopidine caused by Timolol mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[32]
Suprofen	DMKXJZ7	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Suprofen.	Eye anterior segment structural developmental anomaly [LA11]	[33]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Mefenamic acid.	Female pelvic pain [GA34]	[11]
Tolterodine	DMSHPW8	Minor	Decreased metabolism of Ticlopidine caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[34]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Ticlopidine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[35]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Ticlopidine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Tipranavir	DM8HJX6	Major	Increased risk of bleeding by the combination of Ticlopidine and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Ticlopidine caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Ticlopidine caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[15]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[11]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Ticlopidine caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[38]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Ticlopidine caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Alosetron	DML2A03	Moderate	Decreased metabolism of Ticlopidine caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[40]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Ticlopidine caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[41]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[42]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Ticlopidine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[43]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Ticlopidine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[44]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Ticlopidine and Ponatinib.	Mature B-cell lymphoma [2A85]	[45]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Ticlopidine caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[28]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Ticlopidine caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[46]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Ticlopidine and Panobinostat.	Multiple myeloma [2A83]	[22]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Ticlopidine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Ticlopidine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[47]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Ticlopidine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[17]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Ticlopidine and Prasugrel.	Myocardial infarction [BA41-BA43]	[15]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Ticlopidine and Vorapaxar.	Myocardial infarction [BA41-BA43]	[48]
Tirofiban	DMQG17S	Major	Increased risk of bleeding by the combination of Ticlopidine and Tirofiban.	Myocardial infarction [BA41-BA43]	[49]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Ticlopidine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[22]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Sibutramine.	Obesity [5B80-5B81]	[50]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Dexfenfluramine.	Obesity [5B80-5B81]	[50]
Diclofenac	DMPIHLS	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Diclofenac.	Osteoarthritis [FA00-FA05]	[11]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Nepafenac.	Osteoarthritis [FA00-FA05]	[33]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Naproxen.	Osteoarthritis [FA00-FA05]	[11]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Ticlopidine and MK-4827.	Ovarian cancer [2C73]	[15]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Aspirin.	Pain [MG30-MG3Z]	[11]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Etodolac.	Pain [MG30-MG3Z]	[11]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Diflunisal.	Pain [MG30-MG3Z]	[11]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Ibuprofen.	Pain [MG30-MG3Z]	[11]
Nabumetone	DMAT2XH	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Nabumetone.	Pain [MG30-MG3Z]	[11]
Codeine	DMJX6ZG	Moderate	Decreased metabolism of Ticlopidine caused by Codeine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[51]
Rasagiline	DM3WKQ4	Major	Decreased metabolism of Ticlopidine caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[22]
Ropinirole	DMA6S1D	Moderate	Decreased metabolism of Ticlopidine caused by Ropinirole mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[52]
Ketorolac	DMI4EL5	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Ketorolac.	Postoperative inflammation [1A00-CA43]	[11]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Bromfenac.	Postoperative inflammation [1A00-CA43]	[11]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Treprostinil.	Pulmonary hypertension [BB01]	[53]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Epoprostenol.	Pulmonary hypertension [BB01]	[53]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Iloprost.	Pulmonary hypertension [BB01]	[53]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Meloxicam.	Rheumatoid arthritis [FA20]	[11]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Sulindac.	Rheumatoid arthritis [FA20]	[11]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Oxaprozin.	Rheumatoid arthritis [FA20]	[11]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Flurbiprofen.	Rheumatoid arthritis [FA20]	[11]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Fenoprofen.	Rheumatoid arthritis [FA20]	[11]
Indomethacin	DMSC4A7	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Indomethacin.	Rheumatoid arthritis [FA20]	[11]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Tolmetin.	Rheumatoid arthritis [FA20]	[11]
Thioridazine	DM35M8J	Major	Decreased metabolism of Ticlopidine caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[54]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Ticlopidine caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[55]
Asenapine	DMSQZE2	Moderate	Decreased metabolism of Ticlopidine caused by Asenapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[56]
Pimozide	DMW83TP	Moderate	Decreased metabolism of Ticlopidine caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[57]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Ticlopidine and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[58]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Ticlopidine caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[15]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[19]
Caplacizumab	DMPUKA7	Major	Increased risk of bleeding by the combination of Ticlopidine and Caplacizumab.	Thrombocytopenia [3B64]	[22]
Anagrelide	DMSQ8MD	Moderate	Decreased metabolism of Ticlopidine caused by Anagrelide mediated inhibition of CYP450 enzyme.	Thrombocytosis [3B63]	[59]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Ticlopidine and Apixaban.	Thrombosis [DB61-GB90]	[15]
Cangrelor	DM8JRH0	Major	Increased risk of bleeding by the combination of Ticlopidine and Cangrelor.	Thrombosis [DB61-GB90]	[60]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Brilinta.	Thrombosis [DB61-GB90]	[15]
Argatroban	DMFI46A	Major	Increased risk of bleeding by the combination of Ticlopidine and Argatroban.	Thrombosis [DB61-GB90]	[61]
Dicumarol	DMFQCB1	Moderate	Increased risk of bleeding by the combination of Ticlopidine and Dicumarol.	Thrombosis [DB61-GB90]	[19]
Clopidogrel	DMOL54H	Major	Decreased metabolism of Ticlopidine caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[62]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Ticlopidine and Cabozantinib.	Thyroid cancer [2D10]	[63]
Tizanidine	DMR2IQ4	Major	Decreased metabolism of Ticlopidine caused by Tizanidine mediated inhibition of CYP450 enzyme.	Tonus and reflex abnormality [MB47]	[64]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Ticlopidine and Betrixaban.	Venous thromboembolism [BD72]	[60]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ticlopidine 250 mg tablet	250 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Ticlopidine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7307).
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
• [10] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [11] Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc, Palo Alto, CA.
• [12] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [13] Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
• [14] Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
• [15] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [16] Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
• [17] Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
• [18] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [19] Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR "Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients." Ther Drug Monit 17 (1995): 33-8. [PMID: 7725374]
• [20] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [21] Product Information. Fragmin (dalteparin). Pharmacia and Upjohn, Kalamazoo, MI.
• [22] Cerner Multum, Inc. "Australian Product Information.".
• [23] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [24] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4. [PMID: 8913401]
• [25] Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
• [26] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
• [27] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
• [28] Canadian Pharmacists Association.
• [29] Donahue S, Flockhart DA, Abernethy DR "Ticlopidine inhibits phenytoin clearance." Clin Pharmacol Ther 66 (1999): 563-8. [PMID: 10613611]
• [30] Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D "Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19." Biochemistry 40 (2001): 12112-22. [PMID: 11580286]
• [31] Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
• [32] Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
• [33] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [34] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
• [35] Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
• [36] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [37] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [38] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [39] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [40] Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
• [41] Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
• [42] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
• [43] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [44] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [45] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [46] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [47] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [48] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [49] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
• [50] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
• [51] Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
• [52] Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
• [53] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
• [54] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
• [55] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [56] Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
• [57] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ "Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication." Am J Med Sci 309 (1995): 315-6. [PMID: 7771501]
• [58] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
• [59] Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
• [60] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
• [61] Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
• [62] Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
• [63] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [64] Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]